CY1118191T1 - Αναλογα δεοξυνοζιριμυκινης και οι χρησεις τους ως αναστολεις γλυκοζυλοκεραμιδασης - Google Patents

Αναλογα δεοξυνοζιριμυκινης και οι χρησεις τους ως αναστολεις γλυκοζυλοκεραμιδασης

Info

Publication number
CY1118191T1
CY1118191T1 CY20161100964T CY161100964T CY1118191T1 CY 1118191 T1 CY1118191 T1 CY 1118191T1 CY 20161100964 T CY20161100964 T CY 20161100964T CY 161100964 T CY161100964 T CY 161100964T CY 1118191 T1 CY1118191 T1 CY 1118191T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutically acceptable
deoxynosirimycin
dioxynzirimykin
glycosylceramide
analogues
Prior art date
Application number
CY20161100964T
Other languages
Greek (el)
English (en)
Inventor
Johannes Maria Franciscus Gerardus Aerts
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of CY1118191T1 publication Critical patent/CY1118191T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20161100964T 2003-10-29 2016-09-28 Αναλογα δεοξυνοζιριμυκινης και οι χρησεις τους ως αναστολεις γλυκοζυλοκεραμιδασης CY1118191T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03078395A EP1528056A1 (en) 2003-10-29 2003-10-29 Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
EP04793685.1A EP1680403B1 (en) 2003-10-29 2004-10-29 Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
PCT/NL2004/000761 WO2005040118A1 (en) 2003-10-29 2004-10-29 Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors

Publications (1)

Publication Number Publication Date
CY1118191T1 true CY1118191T1 (el) 2017-06-28

Family

ID=34400526

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100964T CY1118191T1 (el) 2003-10-29 2016-09-28 Αναλογα δεοξυνοζιριμυκινης και οι χρησεις τους ως αναστολεις γλυκοζυλοκεραμιδασης

Country Status (14)

Country Link
US (1) US7528153B2 (enExample)
EP (2) EP1528056A1 (enExample)
JP (2) JP5016925B2 (enExample)
AU (1) AU2004284012B2 (enExample)
CA (1) CA2551060C (enExample)
CY (1) CY1118191T1 (enExample)
DK (1) DK1680403T3 (enExample)
ES (1) ES2594356T3 (enExample)
HU (1) HUE029637T2 (enExample)
IL (1) IL175260A0 (enExample)
PL (1) PL1680403T3 (enExample)
PT (1) PT1680403T (enExample)
SI (1) SI1680403T1 (enExample)
WO (1) WO2005040118A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004283631A1 (en) * 2003-10-29 2005-05-06 Genzyme Corporation Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
EP1528056A1 (en) 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
WO2005092334A2 (en) * 2004-03-25 2005-10-06 David Priestman Use of n-substituted imino sugars for appetite suppression
BRPI0517701A8 (pt) 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
FR2887549B1 (fr) * 2005-06-23 2009-07-10 Centre Nat Rech Scient Nouveaux composes de la famille des iminosucres, leurs utilisations, notamment pour le traitement de maladies lysosomales, ainsi que leur procede de preparation
FR2894482A1 (fr) * 2005-12-14 2007-06-15 Galderma Sa Utilisation d'une composition comprenant une association d'hydroquinone,d'acetonide de fluocinolone et de tretinoine, dans le traitement d'l'hyperpigmentation de la peau suite au psoriasis ou a l'eczema
CA2650311A1 (en) * 2006-04-24 2007-11-01 Academisch Medisch Centrum Improved treatment of cystic fibrosis
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
EP2594563B1 (en) 2007-05-31 2018-07-18 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
CA2701649C (en) 2007-10-05 2016-05-24 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
US8497122B2 (en) 2008-04-11 2013-07-30 Washington University Biomarkers for Niemann-pick C disease and related disorders
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
CN102271678B (zh) 2008-10-03 2017-06-30 简詹姆公司 2‑酰胺基丙醇型葡糖神经酰胺合成酶抑制剂
EP2398500B1 (en) * 2009-02-20 2019-03-13 2-BBB Medicines B.V. Glutathione-based drug delivery system
CA2793276A1 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
CN102740852A (zh) * 2009-12-07 2012-10-17 牛津大学之校长及学者 用于抑制破骨细胞形成和/或破骨细胞活化的n-取代的脱氧野尻霉素化合物
US8981083B2 (en) 2010-05-14 2015-03-17 Dana Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
US9301962B2 (en) 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
ES2371398B1 (es) * 2010-06-04 2013-05-20 Bioglane, S.L.N.E. Uso de un iminoazúcar como inhibidor de la adherencia a células epiteliales.
EP2533051A1 (en) 2011-06-06 2012-12-12 Centogene GmbH Method for the diagnosis of Gaucher's disease
US9804152B1 (en) * 2012-08-15 2017-10-31 The Procter & Gamble Company Human ex vivo skin model and its use in methods of identifying modulators of skin inflammation
US9623016B2 (en) 2013-03-15 2017-04-18 Emergent Virology Llc Antibacterial compounds
US20160075651A1 (en) * 2013-05-02 2016-03-17 Unither Virology, Llc Glycolipid inhibition using iminosugars
US20160061849A1 (en) * 2013-05-02 2016-03-03 Unither Virology, Llc Lipidomic biomarkers
EP3024327B1 (en) 2013-07-25 2019-09-04 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
RU2722179C2 (ru) 2014-02-28 2020-05-28 Тэнша Терапеутикс, Инк. Лечение состояний, ассоциированных с гиперинсулинемией
WO2015147639A1 (en) 2014-03-27 2015-10-01 Academisch Medisch Centrum N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
CA2955074A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
JP2017525759A (ja) 2014-08-08 2017-09-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジヒドロプテリジノン誘導体およびその使用
EP3212654B1 (en) 2014-10-27 2020-04-08 Tensha Therapeutics, Inc. Bromodomain inhibitors
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
BR112018004618A2 (pt) 2015-09-11 2018-09-25 Dana-Farber Cancer Institute, Inc. ciano tienotriazoldiazepinas e usos das mesmas
CA2996977A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazolodiazepines and uses thereof
US10913752B2 (en) 2015-11-25 2021-02-09 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibitors and uses thereof
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
US20220257604A1 (en) * 2019-03-08 2022-08-18 University Of Virginia Patent Foundation Compositions and methods for modulating viral infections by regulating glucosylceramides
PH12022552955A1 (en) * 2020-05-07 2024-02-26 Alectos Therapeutics Inc Non-lysosomal glucosylceramidase inhibitors and uses thereof
WO2022227287A1 (zh) * 2021-04-25 2022-11-03 中南大学 Dnj及其衍生物在制备预防和/或治疗肺动脉高压药物中的应用
CN118459393B (zh) * 2024-04-29 2025-11-28 中国科学院成都生物研究所 一类具有α-葡萄糖苷酶抑制活性的D-木糖衍生物及制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2504000B2 (ja) 1986-09-02 1996-06-05 日本新薬株式会社 グルコシルモラノリン誘導体
JP4564108B2 (ja) * 1996-07-15 2010-10-20 ジェンザイム コーポレーション デオキシノジリマイシン誘導体及び該誘導体のグルコシルセラミダーゼ阻害剤としての用途
BR9902585A (pt) 1999-02-11 2000-09-26 Claudio Cerqueira Lopes Um novo processo de sìntese de aza-açúcares com atividade biológica
GB0100889D0 (en) * 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
US6235737B1 (en) 2000-01-25 2001-05-22 Peter Styczynski Reduction of hair growth
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
JP4575156B2 (ja) * 2002-07-17 2010-11-04 アクテリオン ファーマシューティカルズ リミテッド グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体
ES2393919T3 (es) * 2002-07-17 2013-01-02 Actelion Pharmaceuticals Ltd. Derivados de PIPERIDINETRIOL como inhibidores de GLUCOSILCERAMIDA SINTASA
GB0229476D0 (en) 2002-12-17 2003-01-22 Oxford Glycosciences Uk Ltd Novel process
EP1528056A1 (en) 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
AU2004283631A1 (en) * 2003-10-29 2005-05-06 Genzyme Corporation Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
WO2005063706A1 (en) 2003-12-23 2005-07-14 Macrozyme Dnm B.V. Synthesis of nojirimycins
EP2932982B1 (en) 2005-05-17 2018-10-03 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives

Also Published As

Publication number Publication date
WO2005040118A1 (en) 2005-05-06
JP5016925B2 (ja) 2012-09-05
CA2551060C (en) 2012-08-28
EP1528056A1 (en) 2005-05-04
AU2004284012A1 (en) 2005-05-06
EP1680403A1 (en) 2006-07-19
AU2004284012B2 (en) 2010-06-17
US20070066581A1 (en) 2007-03-22
PL1680403T3 (pl) 2017-08-31
PT1680403T (pt) 2016-09-07
CA2551060A1 (en) 2005-05-06
SI1680403T1 (sl) 2017-01-31
JP2012180353A (ja) 2012-09-20
ES2594356T3 (es) 2016-12-19
US7528153B2 (en) 2009-05-05
HUE029637T2 (en) 2017-03-28
JP5730808B2 (ja) 2015-06-10
IL175260A0 (en) 2006-09-05
JP2007509926A (ja) 2007-04-19
DK1680403T3 (en) 2016-09-26
EP1680403B1 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
CY1118191T1 (el) Αναλογα δεοξυνοζιριμυκινης και οι χρησεις τους ως αναστολεις γλυκοζυλοκεραμιδασης
CY1118179T1 (el) Φαρμακευτικη συνθεση
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
CY1119817T1 (el) Στερεα μοναδα δοσολογιας διασπωμενη στο στομα που περιεχει συστατικο οιστετρολης
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
DE60140814D1 (de) N-phenyl-2-pyrimidine-amine derivatives
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
CY1106996T1 (el) Δισκιο με υψηλο φορτιο φαρμακου
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
JOP20200336A1 (ar) طرق إعطاء مثبطات vmat2 معينة
SE0401342D0 (sv) Therapeutic compounds
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
DK1546127T3 (da) Nye pyrimidinamidderivater og anvendelse deraf
SE0402762D0 (sv) Indazole sulphonamide derivatives
SE9900961D0 (sv) Novel compounds
ATE287267T1 (de) Kombinationstherapien mit gefässschädigender aktivität
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CY1116274T1 (el) Παραγωγο τριαζολιου για χρηση στη θεραπεια του νευροπαθητικου πονου και της ινομυαλγιας
CY1108584T1 (el) Παραγωγα 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline ως φαρμακα για τη θεραπεια της στειροτητας
CY1106617T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα συμπλοκο ψευδαργυρου-υαλουρονικου για τη θεραπεια σκληρυνσης κατα πλακας